Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?

Sofia C. Vaz; David Groheux; Thiemo van Nijnatten; Lidija Antunovic; Fatima Cardoso; Felix Mottaghy; Maria Joao Cardoso; Christopher Riedl; Lioe-Fee de Geus-Oei; Gary A. Ulaner

doi:10.1007/s00259-024-07042-9

Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?

Sofia C. Vaz
, David Groheux
, Thiemo van Nijnatten
, Lidija Antunovic
, Fatima Cardoso
, Felix Mottaghy
, Maria Joao Cardoso
, Christopher Riedl
, Lioe-Fee de Geus-Oei
, Gary A. Ulaner^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	801-805
Number of pages	5
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	52
Issue number	3
DOIs	https://doi.org/10.1007/s00259-024-07042-9
Publication status	Published - Feb 2025

Keywords

RECIST
IMMUNOTHERAPY
THERAPY

Access to Document

10.1007/s00259-024-07042-9

Cite this

Vaz, S. C., Groheux, D., van Nijnatten, T., Antunovic, L., Cardoso, F., Mottaghy, F., Cardoso, M. J., Riedl, C., de Geus-Oei, L.-F., & Ulaner, G. A. (2025). Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer? European Journal of Nuclear Medicine and Molecular Imaging, 52(3), 801-805. https://doi.org/10.1007/s00259-024-07042-9

@article{df0150f2c7c84942b3e281e34ca110af,

title = "Editorial Commentary: Should {"}heterogeneous response{"} be considered as new category for assessing treatment response in patients with breast cancer?",

keywords = "RECIST, IMMUNOTHERAPY, THERAPY",

author = "Vaz, \{Sofia C.\} and David Groheux and \{van Nijnatten\}, Thiemo and Lidija Antunovic and Fatima Cardoso and Felix Mottaghy and Cardoso, \{Maria Joao\} and Christopher Riedl and \{de Geus-Oei\}, Lioe-Fee and Ulaner, \{Gary A.\}",

year = "2025",

month = feb,

doi = "10.1007/s00259-024-07042-9",

language = "English",

volume = "52",

pages = "801--805",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "3",

}

Vaz, SC, Groheux, D, van Nijnatten, T, Antunovic, L, Cardoso, F, Mottaghy, F, Cardoso, MJ, Riedl, C, de Geus-Oei, L-F & Ulaner, GA 2025, 'Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?', European Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 3, pp. 801-805. https://doi.org/10.1007/s00259-024-07042-9

Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer? / Vaz, Sofia C.; Groheux, David; van Nijnatten, Thiemo et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 52, No. 3, 02.2025, p. 801-805.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - Editorial Commentary

T2 - Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?

AU - Vaz, Sofia C.

AU - Groheux, David

AU - van Nijnatten, Thiemo

AU - Antunovic, Lidija

AU - Cardoso, Fatima

AU - Mottaghy, Felix

AU - Cardoso, Maria Joao

AU - Riedl, Christopher

AU - de Geus-Oei, Lioe-Fee

AU - Ulaner, Gary A.

PY - 2025/2

Y1 - 2025/2

KW - RECIST

KW - IMMUNOTHERAPY

KW - THERAPY

U2 - 10.1007/s00259-024-07042-9

DO - 10.1007/s00259-024-07042-9

M3 - Editorial

SN - 1619-7070

VL - 52

SP - 801

EP - 805

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 3

ER -